A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan

Ho, 2006, Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan, Bone Marrow Transplant, 37, 569, 10.1038/sj.bmt.1705287 Viprakasit, 2009, Iron chelation therapy in the management of thalassemia: the Asian perspectives, Int J Hematol, 90, 435, 10.1007/s12185-009-0432-0 Porter, 2005, Monitoring and treatment of iron overload: state of the art and new approaches, Semin Hematol, 42, S14, 10.1053/j.seminhematol.2005.01.004 Morris, 2006, Clinical hemoglobinopathies: iron, lungs and new blood, Curr Opin Hematol, 13, 407 Olivieri, 1997, Iron-chelating therapy and the treatment of thalassemia, Blood, 89, 739, 10.1182/blood.V89.3.739 Cabantchik, 2005, LPI-labile plasma iron in iron overload, Best Pract Res Clin Haematol, 18, 277, 10.1016/j.beha.2004.10.003 Fausel, 2010, Iron chelation therapy in myelodysplastic syndromes, Am J Health Syst Pharm, 67, S10, 10.2146/ajhp090654 Inati, 2009, Recent advances in improving the management of sickle cell disease, Blood Rev, 23, S9, 10.1016/S0268-960X(09)70004-9 Cohen, 2004, Thalassemia, Hematology Am Soc Hematol Educ Program, 14, 10.1182/asheducation-2004.1.14 Neufeld, 2006, Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions, Blood, 107, 3436, 10.1182/blood-2006-02-002394 Stumpf, 2007, Deferasirox, Am J Health Syst Pharm, 64, 606, 10.2146/ajhp060405 Porter, 2009, Optimizing iron chelation strategies in beta-thalassaemia major, Blood Rev, 23, S3, 10.1016/S0268-960X(09)70003-7 Wonke, 1998, Combined therapy with deferiprone and desferrioxamine, Br J Haematol, 106, 252 Piga, 2005, Deferiprone: new insight, Ann NY Acad Sci, 1054, 169, 10.1196/annals.1345.019 Peng, 2006, Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan, Hemoglobin, 30, 125, 10.1080/03630260500455581 Kolnagou, 2006, Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassaemia. The Protocol of the International Committee on Oral Chelators, Hemoglobin, 30, 239, 10.1080/03630260600642567 Daar, 2006, Combined therapy with desferrioxamine and deferiprone in beta thalassaemia major patients with transfusional iron overload, Ann Hematol, 85, 315, 10.1007/s00277-005-0075-z Roberts, 2007, Oral deferiprone for iron chelation in people with thalassaemia, Cochrane Database Syst Rev, 3, CD004839 Beutler, 2003, Iron deficiency and overload, Hematology Am Soc Hematol Educ Program, 40, 10.1182/asheducation-2003.1.40 2007 Delea, 2007, Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective, Pharmacoeconomics, 25, 329, 10.2165/00019053-200725040-00005 Cappellini, 2006, A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia, Blood, 107, 3455, 10.1182/blood-2005-08-3430 Dubey, 2007, Deferasirox: the new oral iron chelator, Indian Pediatr, 44, 603 Drummond, 2005 Sonnenberg, 1993, Markov models in medical decision making: a practical guide, Med Decis Making, 13, 322, 10.1177/0272989X9301300409 Lin, 2007, Factors related to thalassemia major patients with serum ferritin level higher than 2,500 ng/ml and their biosocial guiding plan, 153 Fischer, 2003, Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassemia major: application of SQUID biomagnetic liver susceptometry, Br J Haematol, 121, 938, 10.1046/j.1365-2141.2003.04297.x Chern, 2006, Impact of a national betathalassemia carrier screening program on the birth rate of thalassemia major, Pediatr Blood Cancer, 46, 72, 10.1002/pbc.20343 Fausel, 2010, Iron chelation therapy in myelodysplastic syndromes, Am J Health Syst Pharm, 67, S10, 10.2146/ajhp090654 Weinstein, 2003, Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies, Value Health, 6, 9, 10.1046/j.1524-4733.2003.00234.x McLeod, 2009, Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation, Health Technol Assess, 13, 10.3310/hta13010 Hirth, 2000, Willingness to pay for a quality-adjusted life year: in search of a standard, Med Decis Making, 20, 332, 10.1177/0272989X0002000310 Ubel, 2003, What is the price of life and why doesn’t it increase at the rate of inflation, Arch Intern Med, 163, 1637, 10.1001/archinte.163.14.1637